Infections Drive 12% of Cancers Globally, Highlighting Urgent Need for Vaccines

Introduction

A groundbreaking study published in The Lancet Oncology has shed new light on the significant role infections play in the global cancer burden. Researchers estimate that approximately 12% of all cancer cases diagnosed in 2024—equating to 2.3 million instances—can be attributed to infections with viruses, bacteria, or parasites. This finding powerfully underscores the potential of preventive strategies, particularly vaccination, in reducing cancer incidence worldwide.

Key Details

• Global Impact: The analysis, which mapped the impact of 12 cancer-causing pathogens, found that infections were responsible for an estimated 2.3 million new cancer cases in 2024, or about 12% of the total diagnosed that year.
• Leading Pathogens: Just four pathogens account for the vast majority (92%) of infection-related cancers: Helicobacter pylori (760,000 cases, primarily gastric cancer), Human Papillomavirus (HPV) (750,000 cases, including cervical, penile, and throat cancers), Hepatitis B virus (360,000 cases, liver cancer), and Epstein-Barr virus (EBV) (260,000 cases, linked to lymphomas and throat cancers).
• Vaccine Efficacy: The study highlights the success of existing vaccines. Countries with high HPV vaccination rates (over 80%) are beginning to see cervical cancer cases disappear, with some reporting zero cases of HPV-related cancers or deaths in young, vaccinated adults.
• Disparities in Prevention: Despite the proven effectiveness of vaccines, global coverage remains alarmingly low. Only 31% of eligible adolescent girls worldwide received the HPV vaccine, far below the WHO's 90% target. The burden of infection-driven cancers disproportionately affects low- and middle-income countries, which bear 77% of the global load.
• Vaccine Challenges: While vaccines exist for HPV and Hepatitis B, widespread uptake is hampered by cost, accessibility, and misinformation. A vaccine for EBV is still under development due to the virus's complex nature.

Background

The study utilized data from the Global Cancer Observatory's GLOBOCAN database, estimating that around 20 million new cancer cases were diagnosed globally in 2024. By cross-referencing this with data on infection prevalence in cancer patients, researchers were able to quantify the attributable fraction of cancers caused by specific pathogens. This comprehensive approach allowed for an estimation of the burden imposed by 12 key infectious agents known to increase cancer risk.

The identified pathogens include well-known culprits like HPV and Hepatitis B and C, alongside viruses such as HIV and EBV. The analysis revealed a stark concentration of risk, with H. pylori and the viruses HPV, Hepatitis B, and EBV emerging as the dominant drivers of infection-related cancers. This concentration suggests that targeted interventions against these specific agents could yield substantial public health benefits.

Impact Analysis

The implications of this study are profound. It suggests that a significant portion of the global cancer burden is preventable through measures that target infectious agents. Dr. Prashant Mathur, director of India's National Centre for Disease Informatics and Research, noted that when combined with lifestyle modifications—such as reducing tobacco and alcohol consumption, improving diet, increasing physical activity, and mitigating environmental pollution—up to 50-60% of all cancers could be avoidable. This new analysis reinforces the global applicability of such preventive strategies.

The success stories in countries with high HPV vaccination rates, as highlighted by Dr. Rebecca Perkins, an obstetrician-gynecologist at Tufts University School of Medicine, offer a compelling vision for the future. The near-elimination of cervical cancer in highly vaccinated populations demonstrates the power of public health initiatives. However, these successes are not evenly distributed. The study's finding that low- and middle-income countries bear the brunt of infection-driven cancers, including about 81% of HPV-linked cancers, points to a critical need for equitable access to preventive tools.

“The biggest hurdle has been the complexity of the virus. Unlike many other viruses that use just one or two virus proteins to enter cells, EBV uses multiple proteins ... and it hides inside cells for our entire lifetime.”

Broader Context

The challenge of preventing infection-related cancers extends beyond just administering existing vaccines. For HPV, the transition to a single-dose regimen, supported by recent trials, could simplify mass vaccination campaigns by reducing costs and logistical complexities, particularly in resource-limited settings. In the U.S., however, progress is uneven, with some regions lagging in vaccination rates due to parental hesitancy and misconceptions about the vaccine's necessity or timing. Experts emphasize that vaccination cannot occur too early.

For Hepatitis B, a highly effective vaccine exists, recommended for infants shortly after birth. However, recent shifts in vaccination recommendations in some countries, like the U.S. CDC's decision to stop recommending universal vaccination at birth, raise concerns about potentially increasing infection rates and subsequent cancers. The absence of an approved vaccine for EBV presents a different kind of challenge. Claire Shannon-Lowe, a tumor virologist at the University of Birmingham, explains that EBV's complex mechanism of cell entry and its ability to remain dormant within cells have made vaccine development difficult. Yet, growing evidence linking EBV to autoimmune diseases like multiple sclerosis and lupus may provide renewed impetus for vaccine research, potentially leading to a vaccine that could prevent infection and aid in treating associated cancers.

Future Outlook

The path forward involves strengthening preventive measures, expanding vaccine access, and investing in research for new vaccines. For H. pylori, strategies like population-wide screening and treatment are being explored to curb gastric cancer. Vaccine development for this bacterium also requires further investment. The study’s authors acknowledge that the true scale of infection-related cancers might be underestimated due to data gaps, particularly in Africa and other regions with less comprehensive cancer registries. Improving data collection is crucial for a complete understanding of the global burden.

From an economic perspective, investing in prevention yields a higher return than focusing solely on treatment. As Dr. Mathur points out, strengthening preventive aspects is key to achieving long-term gains in public health and reducing the overall societal cost of cancer. The development of an EBV vaccine, spurred by its association with autoimmune diseases, offers a promising future prospect, potentially impacting not only cancer prevention but also the management of EBV-associated cancers and autoimmune conditions.

Conclusion

This comprehensive analysis in The Lancet Oncology provides compelling evidence that infections are a major, yet often overlooked, cause of cancer globally. With 1 in 8 cancer cases attributable to infectious agents, the findings underscore the immense potential of vaccines and other preventive interventions. Addressing the disparities in vaccine access, combating misinformation, and accelerating the development of new vaccines, particularly for pathogens like EBV, are critical steps. By prioritizing prevention, particularly through robust vaccination programs, the world can significantly reduce the future burden of cancer and save millions of lives.